Preview

Russian Journal of Cardiology

Advanced search

Biomarkers associated with atherogenesis: current status and promising areas

https://doi.org/10.15829/1560-4071-2019-12-148-152

Abstract

Biomarkers being used as a laboratory test allow diagnosing the disease at an early stage, confirming diagnostic assumptions or evaluating treatment results. The reveal of biomarkers is inextricably linked to an understanding of the pathogenesis of the disease. As a rule, a biomarker is a soluble molecule participating in the pathological process. The reveal of biomarkers of atherogenesis (BMA) is based on hypotheses of the atherosclerosis development. The formation of atherosclerotic plaques is associated with impaired lipid metabolism, inflammation, fibrosis, calcinosis and oxidative stress. Low-density cholesterol is a recognized BMA in terms of the concept of lipid metabolism disorder. Another concept of atherogenesis is inflammatory theory. To date, a large number of molecules that are involved in the inflammatory process in the formation of atherosclerotic plaques have been studied. For most of these molecules, association with cardiovascular diseases has been proven, but they enter clinical practice very slowly. The most widespread among inflammatory biomarkers of atherogenesis is the highly sensitive C-reactive protein. C-reactive protein is not directly associated with the development of atherosclerosis, however, it is formed in response to the inflammatory reaction, therefore it can be used as a BMA. Its main advantages include stability and well-known reference intervals. Other molecules that can directly participate in the formation of atherosclerotic plaques or lead to their instability are also being studied as BMA. To introduce the use of these markers into routine practice, additional studies are needed to establish reference intervals. In recent years, the role of micro RNA as BMA has been increasingly discussed. Micro RNA molecules have a high stability and indirectly reflect the level of expression of genes involved in the development of atherosclerosis. The determination of BMA directly involved in the formation of plaques will contribute to a more accurate diagnosis and assessment of existing and potential therapy for atherosclerosis.

About the Authors

M. A. Magruk
OOO GEROFARM
Russian Federation
St. Petersburg


A. A. Mosikyan
OOO GEROFARM; Almazov National Medical Research Center
Russian Federation
St. Petersburg


A. Yu. Babenko
Almazov National Medical Research Center
Russian Federation
St. Petersburg


References

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.

2. Deeks J.J., Altman D.G. Diagnostic tests 4: likelihood ratios. BMJ. 2004 Jul 17;329(7458):168-9. doi: 10.1136/bmj.329.7458.168.

3. Libby P., Loscalzo J., Ridker P.M., et al. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018 Oct 23;72(17):2071-2081. doi: 10.1016/j.jacc.2018.08.1043.

4. Mahmood S.S., Levy D., Vasan R.S., et al. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2014 Mar 15; 383(9921): 999–1008. doi: 10.1016/S0140-6736(13)61752-3.

5. Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.

6. Bonaca M.P., Nault P., Giugliano R.P. Et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235.

7. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2019) 00, 178.

8. Taskinen M.R., Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–95. doi: 10.1016/j.atherosclerosis.2015.01.039.

9. Di Pietro N., Formoso G., Pandolfi A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol. 2016 Sep; 84:1-7. doi: 10.1016/j.vph.2016.05.013.

10. Valk F.M., Bekkering S., Kroon J. et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838.

11. Tselepis A.D. Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. J Biomed Res. 2018 Jan 26; 32(1): 13–22. doi: 10.7555/JBR.31.20160009.

12. Aletaha, D., Neogi, T., Silman, A.J., et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81

13. Ridker P.M. A Test in Context: High-Sensitivity C-Reactive Protein. J Am Coll Cardiol. 2016 Feb 16;67(6):712-723. doi: 10.1016/j.jacc.2015.11.037.

14. Ridker P.M., MacFadyen J.G., Everett B.M., et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3.

15. Agarwal I., Arnold A., Glazer N.L., et al. Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study. Atherosclerosis. 2015 Apr;239(2):539-46. doi: 10.1016/j.atherosclerosis.2015.02.020.

16. Biernacka A., Dobaczewski M., Frangogiannis N.G. TGF-β signaling in fibrosis. Growth Factors. 2011 Oct; 29(5): 196–202. doi: 10.3109/08977194.2011.595714.

17. Ketelhuth, D.F.J., Bäck, M. The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep. 2011 Apr;13(2):162-9. doi: 10.1007/s11883-010-0159-7.

18. Goncalves, I., Bengtsson, E., Colhoun, H.M., et al. Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1723-31. doi: 10.1161/ATVBAHA.115.305631.

19. Kinney G.L., Snell-Bergeon J.K., Maahs D.M., et al. Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther. 2011 Mar;13(3):381-7. doi: 10.1089/dia.2010.0175.

20. Prasad, K., Dhar, I., Zhou, Q., et al. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem. 2016 Dec;423(1-2):105-114. doi: 10.1007/s11010-016-2829-4.

21. Prasad, K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2.

22. Szelenberger, R., Kacprzak, M., Saluk-Bijak, J., et al. Plasma MicroRNA as a novel diagnostic. Clin Chim Acta. 2019 Sep 6;499:98-107. doi: 10.1016/j.cca.2019.09.005

23. Cheng Y., Zhang Ch. MicroRNA-21 in Cardiovascular Disease. J. of Cardiovasc. Trans. Res. (2010) 3:251–255. doi: 10.1007/s12265-010-9169-7.


Review

For citations:


Magruk M.A., Mosikyan A.A., Babenko A.Yu. Biomarkers associated with atherogenesis: current status and promising areas. Russian Journal of Cardiology. 2019;(12):148-152. (In Russ.) https://doi.org/10.15829/1560-4071-2019-12-148-152

Views: 1090


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)